Teacher Retirement System of Texas Grows Stake in Cerus Co. (NASDAQ:CERS)

Teacher Retirement System of Texas lifted its position in Cerus Co. (NASDAQ:CERS) by 17.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,634 shares of the biotechnology company’s stock after buying an additional 3,273 shares during the period. Teacher Retirement System of Texas’ holdings in Cerus were worth $128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. Wasatch Advisors Inc. lifted its position in Cerus by 103.4% during the first quarter. Wasatch Advisors Inc. now owns 6,022,961 shares of the biotechnology company’s stock valued at $36,198,000 after purchasing an additional 3,062,266 shares in the last quarter. Kennedy Capital Management Inc. lifted its position in Cerus by 80.4% during the first quarter. Kennedy Capital Management Inc. now owns 1,870,583 shares of the biotechnology company’s stock valued at $11,242,000 after purchasing an additional 833,891 shares in the last quarter. Roubaix Capital LLC purchased a new position in Cerus during the second quarter valued at $3,007,000. Pier Capital LLC lifted its position in Cerus by 57.2% during the first quarter. Pier Capital LLC now owns 1,119,939 shares of the biotechnology company’s stock valued at $6,731,000 after purchasing an additional 407,550 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Cerus by 2.5% during the first quarter. BlackRock Inc. now owns 12,686,269 shares of the biotechnology company’s stock valued at $76,245,000 after purchasing an additional 307,314 shares in the last quarter. Hedge funds and other institutional investors own 88.16% of the company’s stock.

In other Cerus news, Director Daniel N. Swisher, Jr. sold 12,877 shares of the firm’s stock in a transaction dated Wednesday, August 4th. The stock was sold at an average price of $6.25, for a total transaction of $80,481.25. Following the sale, the director now directly owns 106,231 shares of the company’s stock, valued at $663,943.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.72% of the stock is owned by company insiders.

NASDAQ:CERS opened at $6.37 on Tuesday. The company has a quick ratio of 2.34, a current ratio of 2.82 and a debt-to-equity ratio of 0.65. The business’s 50-day simple moving average is $5.82 and its two-hundred day simple moving average is $5.86. The stock has a market cap of $1.09 billion, a PE ratio of -17.69 and a beta of 1.22. Cerus Co. has a 52 week low of $4.67 and a 52 week high of $8.87.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Tuesday, August 3rd. The biotechnology company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.01. The business had revenue of $31.48 million for the quarter, compared to analysts’ expectations of $26.10 million. Cerus had a negative return on equity of 62.92% and a negative net margin of 57.50%. Sell-side analysts anticipate that Cerus Co. will post -0.37 earnings per share for the current fiscal year.

Separately, Zacks Investment Research upgraded Cerus from a “sell” rating to a “hold” rating in a research report on Tuesday, August 3rd.

About Cerus

Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E.

Further Reading: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.